PROTAGONIST THERAPEUTICS INC (PTGX)
US74366E1029 - Common Stock
We assign a fundamental rating of 6 out of 10 to PTGX. PTGX was compared to 565 industry peers in the Biotechnology industry. PTGX has an excellent financial health rating, but there are some minor concerns on its profitability. PTGX is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
PTGX had positive earnings in the past year.
In the past year PTGX had a positive cash flow from operations.
In the past 5 years PTGX always reported negative net income.
PTGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PTGX's Return On Assets of 28.29% is amongst the best of the industry. PTGX outperforms 98.75% of its industry peers.
With an excellent Return On Equity value of 32.12%, PTGX belongs to the best of the industry, outperforming 98.22% of the companies in the same industry.
With an excellent Return On Invested Capital value of 21.06%, PTGX belongs to the best of the industry, outperforming 98.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.29% | ||
| ROE | 32.12% | ||
| ROIC | 21.06% |
ROA(3y)-36.52%
ROA(5y)-35.95%
ROE(3y)-41.46%
ROE(5y)-48.91%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PTGX's Profit Margin of 52.76% is amongst the best of the industry. PTGX outperforms 99.11% of its industry peers.
Looking at the Operating Margin, with a value of 46.05%, PTGX belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 46.05% | ||
| PM (TTM) | 52.76% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTGX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for PTGX has been increased compared to 1 year ago.
PTGX has more shares outstanding than it did 5 years ago.
PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PTGX has an Altman-Z score of 21.08. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.
PTGX's Altman-Z score of 21.08 is amongst the best of the industry. PTGX outperforms 93.40% of its industry peers.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 21.08 |
ROIC/WACC2.03
WACC10.4%
2.3 Liquidity
PTGX has a Current Ratio of 10.70. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
PTGX has a better Current ratio (10.70) than 83.42% of its industry peers.
PTGX has a Quick Ratio of 10.70. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
PTGX's Quick ratio of 10.70 is amongst the best of the industry. PTGX outperforms 83.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.7 | ||
| Quick Ratio | 10.7 |
3. Growth
3.1 Past
PTGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 201.53%, which is quite impressive.
Looking at the last year, PTGX shows a very strong growth in Revenue. The Revenue has grown by 125.73%.
The Revenue has been growing by 14.17% on average over the past years. This is quite good.
EPS 1Y (TTM)201.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.9%
Revenue 1Y (TTM)125.73%
Revenue growth 3Y27.97%
Revenue growth 5Y14.17%
Sales Q2Q%N/A
3.2 Future
PTGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.74% yearly.
Based on estimates for the next years, PTGX will show a very strong growth in Revenue. The Revenue will grow by 55.05% on average per year.
EPS Next Y235.43%
EPS Next 2Y1.19%
EPS Next 3Y-10.47%
EPS Next 5Y21.74%
Revenue Next Year630.78%
Revenue Next 2Y100.45%
Revenue Next 3Y69.07%
Revenue Next 5Y55.05%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 15.28 indicates a correct valuation of PTGX.
Compared to the rest of the industry, the Price/Earnings ratio of PTGX indicates a rather cheap valuation: PTGX is cheaper than 97.15% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of PTGX to the average of the S&P500 Index (28.65), we can say PTGX is valued slightly cheaper.
The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.28 | ||
| Fwd PE | N/A |
4.2 Price Multiples
PTGX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PTGX is cheaper than 97.15% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PTGX is valued cheaper than 98.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.44 | ||
| EV/EBITDA | 10.58 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTGX's earnings are expected to decrease with -10.47% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y1.19%
EPS Next 3Y-10.47%
5. Dividend
5.1 Amount
No dividends for PTGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PROTAGONIST THERAPEUTICS INC
NASDAQ:PTGX (11/20/2024, 8:00:00 PM)
After market: 40.65 0 (0%)40.65
+2 (+5.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.39B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.28 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.06
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.29% | ||
| ROE | 32.12% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 46.05% | ||
| PM (TTM) | 52.76% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.7 | ||
| Quick Ratio | 10.7 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)201.53%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y235.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)125.73%
Revenue growth 3Y27.97%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y